ArticlemSphere2019
Treatment of Virulent Mycobacterium tuberculosis and HIV Coinfected Macrophages with Gallium Nanoparticles Inhibits Pathogen Growth and Modulates Macrophage Cytokine Production.
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Dynamic coordination engineering of gallium biomaterials: A biological accessibility framework for therapeutic biofunction.Bioactive materials · 2027Review
- Gallium-Doped MXene Nanozymes Protect Liver Through Multi-Death Pathway Blockade and Hepatocyte Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Construction of a Subcutaneous Fat Transplantation Model Infected with Mycobacterium.Current medicinal chemistry · 2026Article
- Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review.Current drug delivery · 2025Review
- Efficacy and Possible Mechanism(s) of Action of Gallium Tetraphenylporphyrin Nanoparticles against HIV-TB Coinfection in anACS infectious diseases · 2024Article
- Nano-Medicine for Treatment of Tuberculosis, Promising Approaches Against Antimicrobial Resistance.Current microbiology · 2024Review
- In Silico Analysis of the GaBiomolecules · 2024Article
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria.International journal of molecular sciences · 2021Review
- Levofloxacin-Loaded Nanosonosensitizer as a Highly Efficient Therapy for Bacillus Calmette-Guérin Infections Based on Bacteria-Specific Labeling and Sonotheranostic Strategy.International journal of nanomedicine · 2021Article
- Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies.Emerging topics in life sciences · 2020Review
- Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tuberculosis (TB), caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.